Improved Management of Soft Tissue Sarcomas Patients With an Optimized and Innovative Sorting Technology for Circulating Tumor Cells

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Inclusion Criteria:

* Male or female patients ≥ 18 years at the day of consenting;
* Histologically confirmed diagnosis of Soft Tissue Sarcoma (STS) excepted GIST.
* Metastatic disease or unresectable locally advanced malignancy for which standard therapy by anthracycline is decided;
* At least one measurable lesion as per RECIST version 1.1.;
* ECOG Performance Status of 0-2;
* Patients must have an adequate organ and bone marrow function at baseline;
* Patient should understand, sign, and date the written voluntary informed consent form prior to any protocol-specific procedures performed and should be able and willing to comply with procedures as per protocol;
* Covered by a medical insurance.

Exclusion Criteria:

* Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results;
* Prior treatment with anthracycline;
* History of other malignancy other than study disease (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix) unless the patient has been free of disease for at least 3 years;
* Metabolic syndrome;
* Pregnant or breast-feeding woman criteria